In ADHD, decades of imaging and pharmacologic data implicate the dysregulation of dopamine transporter (DAT) function and broader catecholaminergic signaling as central to the manifestations of inattention, impulsivity, and hyperactivity (e.g., refs. [5,6]). Here, SLC6A3 is linked to attention deficit-hyperactivity disorder.